Close Menu
  • Home
  • Diabetes
  • Fitness
  • Heart Disease
  • Mental
  • Physical
  • Wellness
  • Yoga
  • Health

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

The percentage of young adults receiving mental health treatment increased by 45% from 2019 to 2022, the largest increase of any age group.

August 1, 2024

Desert Healthcare, Tenet to renew non-compete clause again, vote next week

August 1, 2024

Personalized health coaching may improve cognitive function and reduce dementia risk in older adults

August 1, 2024
Facebook X (Twitter) Instagram
Health Medic NewsHealth Medic News
  • Home
  • About
  • Advertise
  • Contact us
  • DMCA Notice
  • Privacy Policy
  • Terms of Use
  • Home
  • Diabetes

    Analysis of Tandem Diabetes Care (NASDAQ:TNDM) and SeaStar Medical (NASDAQ:ICU)

    June 19, 2024

    Diabetes costs in the UK could reach £14 billion, study finds

    June 19, 2024

    Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study

    June 18, 2024

    Novo Nordisk considers adding 1,000 jobs in Johnston County as sales of weight-loss drug surge

    June 18, 2024

    Cost of devastating complications highlights need for urgent reform of diabetes care in the UK

    June 18, 2024
  • Fitness

    “National Fitness Day” is the next Apple Watch challenge to be held in China

    July 30, 2024

    The Pininfarina Sintesi is now my favorite fitness tracker, but there’s one thing I’d change.

    July 30, 2024

    Fitness Corner: Exercise and our own mortality

    July 30, 2024

    Fitness World Canada Hosts First Spartan DEKA Event in Surrey

    July 30, 2024

    New Franklin Regional boys soccer coach focuses on building trust, fitness

    July 30, 2024
  • Heart Disease

    Blood test warns of hidden heart disease risk

    July 30, 2024

    Loss of teeth may be a sign of serious heart disease

    July 30, 2024

    Researchers warn that removing race from the heart disease risk equation could lead to 16 million people not taking their medications

    July 29, 2024

    Study identifies 18 proteins associated with heart failure and frailty

    July 29, 2024

    Combined prostate cancer treatment increases risk of heart disease

    July 29, 2024
  • Mental

    Addressing adolescent mental health – the importance of early intervention and support

    June 18, 2024

    MAFS’ Dom updates fans on mental health and the future of his podcast

    June 18, 2024

    Connecting to mental health services is as easy as picking up the phone

    June 18, 2024

    Oklahoma Governor Stitt Opposes Mental Health Consent Decree

    June 18, 2024

    Hand to Hold provides mental health support to families in Texas Children’s Hospital’s NICU

    June 17, 2024
  • Physical

    One-of-a-kind Wu-Tang Clan album to be screened at Australian museum

    June 16, 2024

    Interview: Annie Weisman and Closing the Final Chapter of ‘Physical’

    June 16, 2024

    Physiotherapy helps counter the effects of chemotherapy | News, Sports, Jobs

    June 16, 2024

    Barcelona’s new manager not obsessed with physical development

    June 16, 2024

    YouTuber ImAllexx comes under fire for allegations of physical abuse against ex-girlfriend

    June 15, 2024
  • Wellness

    Top Medical Tourism Destinations: A Global Overview | Corporate Wellness

    March 29, 2024

    OACEUS brings a new way to wellness

    March 29, 2024

    Spotlight on the best countries for medical tourism in 2024 | Corporate Wellness

    March 29, 2024

    Digging Deeper into Medical Tourism: Origins and Operations | Corporate Wellness

    March 29, 2024

    Identifying leading medical tourism organizations around the world | Corporate Wellness

    March 29, 2024
  • Yoga

    Body and mind: Epilepsy patients may benefit from yoga

    July 5, 2024

    Lenovo Yoga Pro 9i 16 (2024) review: A+ multi-threading

    July 5, 2024

    The Lenovo Yoga Slim 7x might be the best deal among the new Snapdragon AI PCs

    July 5, 2024

    A Minute with Stavri Ioannou, Yoga Teacher, Mindfulness Educator, and Founder of Kids Alternativities

    July 5, 2024

    7 Places to Work Out Outdoors on the East End This Summer

    July 5, 2024
  • Health

    The percentage of young adults receiving mental health treatment increased by 45% from 2019 to 2022, the largest increase of any age group.

    August 1, 2024

    Desert Healthcare, Tenet to renew non-compete clause again, vote next week

    August 1, 2024

    Personalized health coaching may improve cognitive function and reduce dementia risk in older adults

    August 1, 2024

    Troy University’s College of Health and Human Services to change name effective August 1

    July 30, 2024

    Health Examination

    July 30, 2024
Health Medic NewsHealth Medic News
Home » New Drug for Fatal Heart Failure Proves Safe and Effective in Phase 3 Trial | MUSC
Heart Disease

New Drug for Fatal Heart Failure Proves Safe and Effective in Phase 3 Trial | MUSC

perbinderBy perbinderJanuary 16, 2024No Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Reddit WhatsApp Email
Share
Facebook Twitter LinkedIn Pinterest WhatsApp Email


The heart is a vital muscle that beats over 100,000 times a day, delivering oxygen and nutrients to organs to maintain healthy bodily function. Unfortunately, heart failure affects an estimated 6.2 million people in the United States and a staggering 64 million people worldwide.

Among older patients with heart failure or abnormally thickened hearts, one in five suffer from the late-diagnosed, progressive and fatal transthyretin amyloid cardiomyopathy (ATTR-CM). The disease, which can be inherited or occurring naturally, is caused by the accumulation of abnormally folded transthyretin (TTR) protein in the heart. These protein deposits weaken the heart muscle and, over time, severely limit cardiac function, leading to heart failure.

Patients with the most common form of ATTR-CM are often misdiagnosed in the clinic due to limited knowledge about the disease and symptoms that mimic other common heart-related diseases. Additionally, they also suffer from a shortage of approved medications, as the only treatment specifically indicated for the most common form of ATTR-CM costs approximately $225,000 per year and is not readily available.

“Early in my career, I was frustrated by the lack of a cure. [for ATTR-CM]”The first patient seen in 2017 had a three-year prognosis. Six and a half years later, this same patient, one of the first participants in MUSC’s Phase 2 trial, appears to be on the mend with Acoramidis.” –Daniel Judge, MD

Investigators from the ATTRibute-CM Phase 3 trial report in the New England Journal of Medicine that the novel drug Acoramidis is promising and safe for ATTR-CM. Their data suggest that Acoramidis almost completely stabilizes the TTR protein, potentially slowing or halting disease progression. Based on 30-month efficacy and safety data from this randomized, multicenter, controlled trial, BridgeBio (Palo Alto, CA) is seeking U.S. Food and Drug Administration (FDA) approval for use in these patients.

“We hope that FDA approval of this drug will bring competition to the market and bring down the cost of this very expensive drug,” said Daniel Judge, MD, a cardiologist at the Medical University of South Carolina, an investigator in ATTRibute-CM and co-leader of the trial’s steering committee.

Judge and his Stanford colleague, Isabella Graef, MD, PhD, have spent years researching and developing new treatments for these patients. Graef led the development of new drugs that target the misfolded proteins at the heart of the disease, and Judge has since been deeply involved in Phase 2 and 3 clinical trials, testing the new drugs in the MUSC clinic. In fact, MUSC was one of the first centers in the world to enroll patients in the ATTRibute-CM Phase 3 trial.

In the photo above, the right side of the heart has TTR amyloid buildup, which makes it appear lighter and thicker. When the heart has amyloid, it can't compress and relax as well as a normal heart. Image courtesy of Dr. Daniel Judge
In the photo above, the right side of the heart has TTR amyloid, which makes the heart appear brighter and thicker. When the heart has amyloid, it can’t compress and relax as well as a normal heart. Image courtesy of Dr. Daniel Judge.

ATTRibute-CM researchers found that Acoramidis binds to the circulating TTR protein and prevents it from being deposited as amyloid. Compared to placebo, Acoramidis reduced hospitalizations for heart-related events, reduced cardiac congestion as measured by blood tests, and increased six-minute walk distance.

According to data Judge presented at the American Heart Association, during the study period, the number of people who needed to be treated with Acoramidis to prevent one cardiovascular hospitalization per year was five. Overall, adverse events from treatment were low and similar in both the Acoramidis and placebo groups, indicating the drug is safe. These data offer great hope for patients with ATTR-CM, suggesting that Acoramidis has the potential to halt the progression of the disease and increase survival rates.

Judge, who has practiced cardiology for over 20 years and specializes in translational research in cardiac disease, has recruited and followed several patients in clinical trials of Acoramidis. Judge and his collaborators have watched the drug progress through translational testing and have seen it provide direct benefit to real patients suffering from ATTR-CM.

“Earlier in my career, I was frustrated by the lack of a cure, so I am pleased with the success of the new ATTR-CM trial,” said Judge. “The first patient I saw in 2017 had a three-year prognosis. Six and a half years later, this same patient, one of the first participants in MUSC’s Phase 2 trial, appears to be on the mend thanks to Acoramidis.”

“If we can stabilise the disease, it is expected that the condition of the heart will gradually improve. If we can safely and effectively halt the disease progression with Acoramidis, it has the potential to improve the quality and quantity of life for patients suffering from ATTR-CM around the world.”

reference

Gillmore JD, Judge DP, Cappelli F, et al; ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024 Jan 11;390(2):132-142. doi: 10.1056/NEJMoa2305434. PMID: 38197816.



Source link

perbinder
  • Website

Related Posts

Blood test warns of hidden heart disease risk

July 30, 2024

Loss of teeth may be a sign of serious heart disease

July 30, 2024

Researchers warn that removing race from the heart disease risk equation could lead to 16 million people not taking their medications

July 29, 2024

Leave A Reply Cancel Reply

Don't Miss
Blog

The percentage of young adults receiving mental health treatment increased by 45% from 2019 to 2022, the largest increase of any age group.

By perbinderAugust 1, 20240

A new analysis from KFF finds that the rate of young adults (ages 18-26) receiving…

Desert Healthcare, Tenet to renew non-compete clause again, vote next week

August 1, 2024

Personalized health coaching may improve cognitive function and reduce dementia risk in older adults

August 1, 2024

Troy University’s College of Health and Human Services to change name effective August 1

July 30, 2024
Our Picks

Top Medical Tourism Destinations: A Global Overview | Corporate Wellness

March 29, 2024

OACEUS brings a new way to wellness

March 29, 2024

Spotlight on the best countries for medical tourism in 2024 | Corporate Wellness

March 29, 2024

Digging Deeper into Medical Tourism: Origins and Operations | Corporate Wellness

March 29, 2024
About Us

Welcome to Health Medic News, your trusted source for comprehensive information and insights on health-related topics. At Health Medic News, we are dedicated to providing reliable and up-to-date content to help our readers make informed decisions about their health and well-being.

Our Mission

At Health Medic News, our mission is to empower individuals with the knowledge and resources they need to live healthier lives. We strive to deliver high-quality content that educates, inspires, and motivates our readers to take control of their health and make positive lifestyle changes

Our Picks

“National Fitness Day” is the next Apple Watch challenge to be held in China

July 30, 2024

The Pininfarina Sintesi is now my favorite fitness tracker, but there’s one thing I’d change.

July 30, 2024

Fitness Corner: Exercise and our own mortality

July 30, 2024

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

ads
ads
ads
Facebook X (Twitter) Instagram Pinterest
  • Home
  • About
  • Advertise
  • Contact us
  • DMCA Notice
  • Privacy Policy
  • Terms of Use
© 2025 healthmedicnews. Designed by healthmedicnews.

Type above and press Enter to search. Press Esc to cancel.